153805-39-1Relevant articles and documents
Evaluation of a Vitamin-Cloaking Strategy for Oligopeptide Therapeutics: Biotinylated HIV-1 Protease Inhibitors
Islam, Imadul,Ng, Ka-yun,Chong, Kong Teck,McQuade, Thomas J.,Hui, John O.,et al.
, p. 293 - 304 (2007/10/02)
The outstanding limitations to the oligopeptide as a therapeutic agent are poor oral availability and rapid biliary clearance.To address these concerns a series of eight peptidic HIV-1 protease inhibitors containing the structural segment of the vitamin b